Piracetam activates the metabolic processes in the brain by enhancing the energy and protein metabolism, accelerate the utilization of glucose by cells and increase deca durabolin their resistance to hypoxia; interneuronal improves transmission in the central nervous system, improves the regional blood flow in the ischemic zone.
Cinnarizine – selective blocker of slow calcium channels inhibits calcium ion entry into cells and reduces their content in the depot plasmolemma reduces the tonus of smooth muscle of the arterioles, reduces their response to biogenic vasoconstrictors (epinephrine, norepinephrine, dopamine, angiotensin, vasopressin).It has a vasodilating effect (particularly with regard to vessels of the brain, strengthening anti-hypoxic effect of piracetam), without significant effects on blood pressure. Exhibits mild antihistamine activity, reduces the excitability of the vestibular apparatus, lowers the tone of the sympathetic nervous system. Erythrocyte membrane elasticity increases, their ability to deform, reducing blood viscosity.
The drug is rapidly and completely absorbed from the gastrointestinal tract. The maximum concentration in plasma is created piracetam in 2-6 hours. The maximum concentration in the cerebrospinal fluid – 2-8 hours. Bioavailability is 100%. The plasma protein does not bind. It penetrates into all organs and tissues, passes the placental barrier. Selectively accumulates in the cerebral cortex, primarily in the frontal, parietal, and occipital lobes, cerebellum, and basal ganglia. Do not metabolized. After 30 hours more than 95% is excreted by the kidneys.
The maximum concentration in plasma is created cinnarizine 1-4 hours. The plasma protein binds to 91%. Actively and completely metabolized. The half-life is 4 hours. 1/3 of the metabolites excreted in the urine, 2/3 – with the feces.
Cerebrovascular insufficiency (atherosclerosis of brain vessels, a recovery period of ischemic and hemorrhagic stroke, traumatic brain injuries, encephalopathies of various origins), intoxication; other central nervous system deca durabolin disorders associated with decreased intellectual-mental functions (memory impairment, attention, mood), psycho-organic syndrome with prevalence of signs of fatigue and adinamii, asthenic syndrome; labirintopatii, Meniere’s syndrome; backlog of intellectual development in children, prevention of migraine and kinetoses.
Individual intolerance, severe liver and / or kidney disease, parkinsonism, pregnancy, lactation, children under 5 years.
Dosing and Administration
Inside. The usual dose for adults – 1-2 tablets three times a day for 1-3 months depending on the severity of the disease. Babies – 1-2 tablets 1-2 times daily. Do not apply more than 3 months.
Dyspepsia, headache, sleep disturbances. Rarely – allergic reactions such as skin rash.
Interaction with other drugs
When concomitantly may increase sedative effect of oppressive central nervous system, as well as alcohol, nootropic and antihypertensive agents. Vasodilators increase the effect of the drug. It reduces the effect of antihypertensive drugs.
Improves tolerability of antipsychotic drugs and tricyclic antidepressants.
The drug should be used with caution in people with liver disease and / or kidney. In cases of mild to moderate renal insufficiency (especially if creatinine clearance less than 60 mL / min) should reduce or increase the therapeutic dose intervals between doses. In patients with impaired liver function is necessary to monitor the content of liver enzymes.
Avoid drinking alcohol during treatment.
The drug deca durabolin should be carefully assign at elevated intraocular pressure, as well as in Parkinson’s disease.
Driving vehicles and using machinery.